How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,554 results for

E/M Examination Criteria

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Evidence brief on the role of bariatric surgery in super obesity (BMI > 50 kg/m^2)

text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured (...) Evidence brief on the role of bariatric surgery in super obesity (BMI > 50 kg/m^2) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO

102. Suspected neurological conditions: recognition and referral

the face (trigeminal neur y touching the face (trigeminal neuralgia) algia) 1.3.2 Refer adults with unilateral facial pain that is triggered by touching the affected part of the face (trigeminal neuralgia) and is refractory to treatment, in line with the NICE guideline on neuropathic pain in adults. Scalp tenderness or ja Scalp tenderness or jaw claudication suggestiv w claudication suggestive of tempor e of temporal arteritis al arteritis 1.3.3 For adults with scalp tenderness or jaw claudication (...) guideline on stroke and transient ischaemic attack in over 16s. Rapidly progressiv Rapidly progressive unsteady gait (gait ataxia) e unsteady gait (gait ataxia) 1.4.2 Refer urgently adults with rapidly (within days to weeks) progressive unsteady gait (gait ataxia) for neurological assessment. Gr Gradually progressiv adually progressive unsteady gait (gait ataxia) e unsteady gait (gait ataxia) 1.4.3 Refer adults with gradually progressive unsteady gait (gait ataxia) for neurological assessment and: take

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

103. Prostate cancer: diagnosis and management

people who have had a negative first prostate biopsy. Discuss with the person that: there is still a risk that prostate cancer is present and and the risk is slightly higher if any of the following risk factors are present: the biopsy showed high-grade prostatic intra-epithelial neoplasia (HGPIN) the biopsy showed atypical small acinar proliferation (ASAP) abnormal digital rectal examination. [2014] [2014] If the MRI or biopsy is negativ If the MRI or biopsy is negative e 1.2.10 For people (...) the 2019 recommendations on MRI and biopsy and how they might affect practice, see rationale and impact. Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 511.2.6 Help people decide whether to have an MRI or prostate biopsy by discussing: their prostate-specific antigen (PSA) level their digital rectal examination (DRE) findings (including an estimate of prostate

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

104. Hypertension in pregnancy: diagnosis and management

10 years body mass index (BMI) of 35 kg/m 2 or more at first visit family history of pre-eclampsia multi-fetal pregnancy. [2010, amended 2019] [2010, amended 2019] Other pharmaceutical agents Other pharmaceutical agents 1.1.4 Do not use the following to prevent hypertensive disorders during pregnancy: nitric oxide donors progesterone diuretics low molecular weight heparin. [2010] [2010] Nutritional supplements Nutritional supplements 1.1.5 Do not recommend the following supplements solely (...) with the aim of preventing hypertensive disorders during pregnancy: magnesium folic acid antioxidants (vitamins C and E) Hypertension in pregnancy: diagnosis and management (NG133) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 54fish oils or algal oils garlic. [2010] [2010] Diet Diet 1.1.6 Do not recommend salt restriction during pregnancy solely to prevent gestational hypertension or pre-eclampsia. [2010] [2010

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

105. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01215851 Recruitment Status : Completed First Posted : October 7, 2010 Results First Posted : April 1, 2016 Last Update Posted : February 28

2010 Clinical Trials

106. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma Dar Daratumumab with bortezomib and atumumab with bortezomib and de dexamethasone for pre xamethasone for previously treated viously treated multiple m multiple my yeloma eloma T echnology appraisal guidance Published: 10 April 2019 nice.org.uk/guidance/ta573 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) received at least one prior therapy' . Dosage in Dosage in the the mark marketing eting authorisation authorisation Daratumumab 16 mg/kg body weight is administered by intravenous infusion every week for weeks 1 to 9, every 3 weeks for weeks 10 to 24 and every 4 weeks from week 25 onwards. Bortezomib is administered by subcutaneous injection at a dose of 1.3 mg/m 2 twice weekly on days 1, 4, 8 and 11 for 8×21-day cycles. Dexamethasone is administered orally at a dose of 80 mg weekly. Price Price

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

107. Age-related macular degeneration

techniques with their family members or carers (as appropriate). Monitoring for late AMD (wet activ Monitoring for late AMD (wet active e) ) 1.7.8 Offer people with late AMD (wet active) ongoing monitoring with OCT for both eyes. 1.7.9 Offer fundus examination or colour photography if OCT appearances are stable, but: there is a decline in visual acuity or or the person reports a decline in visual function. 1.7.10 Consider FFA to identify unrecognised neovascularisation if OCT appearances are stable (...) (AREDS 2001) examined the effect of antioxidant supplementation on AMD progression using the AREDS formation, which included beta carotene, vitamin E, vitamin C and zinc. Although the study showed some beneficial effects of the combined antioxidant supplementation in a subgroup of participants, the effects of each of the formula components on AMD progression were unclear. Additionally, 1 of the ingredients (beta carotene) in the AREDS 2001 formulation is associated with a possible risk of lung cancer

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

108. Chronic heart failure in adults: diagnosis and management

services if needed. [2018] [2018] Care after an acute e Care after an acute ev vent ent For recommendations on the diagnosis and management of acute heart failure see NICE's guideline on acute heart failure. 1.1.5 People with heart failure should generally be discharged from hospital only when their clinical condition is stable and the management plan is optimised. Timing of discharge should take into account the wishes of the person and their family or carer, and the level of care and support that can (...) if appropriate, and all health and social care professionals involved in their care. [2018] [2018] 1.2 Diagnosing heart failure Symptoms, signs and in Symptoms, signs and inv vestigations estigations 1.2.1 T ake a careful and detailed history, and perform a clinical examination and tests to confirm the presence of heart failure. [2010] [2010] 1.2.2 Measure N-terminal pro-B-type natriuretic peptide (NT-proBNP) in people with suspected heart failure. [2018] [2018] Chronic heart failure in adults: diagnosis

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

109. Chronic obstructive pulmonary disease in over 16s: diagnosis and management

Chronic obstructive pulmonary disease in over 16s: diagnosis and management Chronic obstructiv Chronic obstructive pulmonary disease in e pulmonary disease in o ov ver 16s: diagnosis and management er 16s: diagnosis and management NICE guideline Published: 5 December 2018 nice.org.uk/guidance/ng115 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) is purely arbitrary response to long-term therapy is not predicted by acute reversibility testing. [2004] [2004] 1.1.19 Untreated COPD and asthma are frequently distinguishable on the basis of history (and examination) in people presenting for the first time. Whenever possible, use features from the history and examination (such as those listed in table 3) to differentiate COPD from asthma. For more information on diagnosing asthma, see the NICE guideline on asthma. [2004, amended 2018] [2004, amended

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

110. Physical examination

, and mammograms or prostate exams depending on gender. Pre-employment examinations [ ] Pre-employment examinations are screening tests which judge the suitability of a worker for hire based on the results of their physical examination. [ ] This is also called pre-employment medical clearance . Many employers believe that by only hiring workers whose physical examination results pass certain exclusionary criteria, their employees collectively will have fewer absences due to sickness, fewer workplace injuries (...) ; 25(1): 55-57. . ^ Mahmud, Norashikin; Schonstein, Eva; Schaafsma, Frederieke; Lehtola, Marika M; Fassier, Jean-Baptiste; Reneman, Michiel F; Verbeek, Jos H; Mahmud, Norashikin (2010). "Pre-employment examinations for preventing occupational injury and disease in workers". Cochrane Database of Systematic Reviews (12): CD008881. : . . ^ (February 2014), , : an initiative of the , American College of Occupational and Environmental Medicine , retrieved 24 February 2014 , which cites Talmage, J

2012 Wikipedia

111. Children and young people exposed prenatally to alcohol

for the assessment and diagnosis of children and young people affected by PAE. It includes evidence-based recommendations on measurement of alcohol consumption in pregnancy and consensus-based recommendations on: y identification of children at risk of FASD y criteria for diagnosis and use of FASD as a descriptor y medical assessment y physical examination y sentinel features y neurodevelopmental assessment y the multidisciplinary assessment team y special considerations in the neurodevelopmental assessment y (...) The need for guidance 1 1.2 Remit of the document 3 1.3 Definitions and terminology 3 1.4 Origin of this guidance 8 1.5 Statement of intent 9 2 Identification of children at risk of FASD 10 2.1 Maternal alcohol history 10 3 Identification and assessment of children and young people affected by prenatal alcohol exposure 15 3.1 Diagnostic criteria 15 3.2 Medical assessment 17 3.3 Sentinel facial features 18 3.4 Neurodevelopmental assessment 19 3.5 Special considerations in the assessment of infants

2019 SIGN

112. Managing opioid use disorder in primary care: PEER simplified guideline

CFPlus.* Correspondence Dr Christina Korownyk; e-mail cpoag@ualberta.ca References 1. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in Canada (January 2016 to March 2018). Ottawa, ON: Public Health Agency of Canada; 2018. 2. Gomes T, Khuu W, Martins D, Tadrous M, Mamdani MM, Paterson JM, et al. Contributions of pre- scribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ (...) edition, criteria; however, the definition has changed over time. Given this inconsistent definition and differing study designs, a reasonable estimate of OUD risk after initial opioid prescription might be 4.7%, recognizing that stud- ies range broadly from 0% to 34%. 7-14 In response to the number of Canadians with OUD and the number of opioid- related deaths, the federal government launched a Canadian drugs and substances strategy. 15,16 In line with this strategy, national methadone prescribing

2019 CPG Infobase

113. Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08

Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Addendum A18-39 Version 1.0 Lumacaftor/ivacaftor – Addendum to Commission A18-08 10 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - IQWiG employees involved in the addendum: ? Natalia Wolfram ? Lars Beckmann ? Volker Vervölgyi Keywords: lumacaftor, ivacaftor (...) . Physiotherapy d No physiotherapy at baseline 10 (9.7) 16 (15.8) Physiotherapy at baseline 93 (90.3) c 85 (84.2) c Physiotherapy at week 24 89 (86.4) c 84 (83.2) c Initiation of physiotherapy between baseline and week 24 2 (1.9) c, e 4 (4.0) c Dietary measures Not reported Not reported f a: Number of randomized patients. Values that are based on other patient numbers are marked in the corresponding line if the deviation is relevant. b: Systemic antibiotics and drugs for mycobacteria, including all with any

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

114. Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V

2017 Internal Commission No.: A17-63 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A17-63 Version 1.0 Dupilumab (atopic dermatitis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Enno Schmidt, Clinic for Dermatology, University (...) Treatment duration: 52 weeks Observation: outcome- specific, follow-up: 12 weeks d 162 study centres in Australia, North America, Europe and Asia 10/2014–10/2016 e First data cut-off: 27 April 2016 f Second data cut-off: 16 December 2016 g Primary: EASI 75 h , IGA Secondary: morbidity, health-related quality of life, side effects a: Primary outcomes include information without consideration of the relevance for this benefit assessment. Secondary outcomes exclusively include information on the relevant

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

115. Air pollution: outdoor air quality and health

the local effect on air pollutant emissions to demonstrate the benefits of training on fuel use and air quality. Procuring public sector v Procuring public sector vehicles ehicles 1.4.6 Consider making low vehicle emissions (nitrogen oxides and particles) one of the criteria when making routine procurement decisions. This could include selecting low-emission vehicles, including electric vehicles. See how the committee made recommendations 1.4.1 to 1.4.6. Air pollution: outdoor air quality and health (...) is usually expressed in micrograms per m 3 of air. [2] The UK is divided into 43 zones for assessing air quality and reporting compliance with EU targets. These zones generally include more than 1 local authority (Air quality plan for the achievement of EU air quality limit values for nitrogen dioxide (NO 2 ) in the UK, 2015 Department for Environment, Food and Rural Affairs.) Air pollution: outdoor air quality and health (NG70) © NICE 2019. All rights reserved. Subject to Notice of rights (https

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

116. Cystic fibrosis: diagnosis and management

, for guidance on joint responsibility and working together with other organisations. 1.4 Complications of cystic fibrosis 1.4.1 Be aware that people with cystic fibrosis are at risk of the following common complications: being underweight meconium ileus (affects 1 in 7 newborn babies) fat-soluble vitamin deficiencies (including vitamins A, D, E and K) distal intestinal obstruction syndrome muscle pains and arthralgia Cystic fibrosis: diagnosis and management (NG78) © NICE 2019. All rights reserved. Subject (...) of clinical history and medicines adherence, and a physical examination with measurement of weight and length or height Cystic fibrosis: diagnosis and management (NG78) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 15 of 43measurement of oxygen saturation taking respiratory secretion samples for microbiological investigations, using sputum samples if possible, or a cough swab or nasal pharyngeal aspirate (NPA) lung

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

117. Traumatic Brain Injury and Dementia

, or royalties) that conflict with material presented in the report. Evidence Brief: TBI and Dementia Evidence Synthesis Program i TABLE OF CONTENTS Executive Summary 1 Key Findings 1 Evidence Brief 4 Introduction 4 Purpose 4 Background 4 Scope 6 Key questions 6 Eligibility criteria 6 Methods 8 Results 9 Literature Flow 9 Literature Overview 9 Key Question 1: What is the comparative prevalence of dementia between Veterans and the civilian population? 10 KQ1a: Does the prevalence of dementia in Veterans vary (...) studies. Regarding unmeasured confounding of the association between dementia and TBI, many demographic, medical, psychiatric, genetic, and lifestyle risk factors have been reported, including, age, sex, Apolipoprotein E polymorphisms, alcohol use, smoking, prescription opioid misuse, diabetes, hypertension, and others. 9-11 These factors may have an impact on the development of dementia and may vary between TBI and non-TBI groups within studies. Additionally, TBI, dementia, and other mental health

2019 Veterans Affairs Evidence-based Synthesis Program Reports

118. Best practice for managing outpatient bookings

weeks or months in advance, rather each day starts with a sizable share of the day’s appointments left open, and the remainder booked for those who elected not to come to the office on the day they called. 5 Length of in person visits Using fewer and longer in-person visits and designated patient outreach, Group Health teams were able to integrate e-mail messages, telephone visits, and proactive care activities into their everyday work flow with a significant decrease in provider burnout. 5 Schedule (...) it is in the best clinical interests of the patient or part of the clinical pathway for which the patient is being treated. The Alfred, Australia 4 The Alfred have developed a GP electronic referral system and education program. The e-referral system covers 3 types of referral (generic referral, speciality unit referral and condition specific referral) was trialled in 5 GP practices. The referral processing time went from 7 days to 1 day with no rejected referrals (18% prior). Referral time to triage down

2019 Monash Health Evidence Reviews

119. IV night teams: Impact on Infection rates, insertion success and deskilling

Epidemiol. 2013 Sep;34(9):908-18. 25. Golombek SG, Rohan AJ, Parvez B, et al. Proactive" management of percutaneously inserted central catheters results in decreased incidence of infection in the ELBW population. J Perinatol. 2002 Apr- May;22(3):209-13. 26. Brown, P. (1984). An IV specialty team can mean savings for hospital and patient. NITA, 7, 387-388. 27. McDiarmid S, Scrivens N, Carrier M, Sabri E, Toye B, Huebsch L, Fergusson D. Outcomes in a nurse- led peripherally inserted central catheter (...) Rickard and Dr Peter Carr were consulted about your questions and they indicated that they were not aware of any research on the effectiveness of IV night teams. Scientific and grey literature databases were searched to find both synthesised and primary evidence on IV night teams, infection rates and deskilling. Articles were screened and selected according to the inclusion/exclusion criteria in Table A1 (appendix). Only articles published in English were considered. A summary of findings are included

2019 Monash Health Evidence Reviews

120. Informing best practice in writing discharge summaries

associated with a discharge summary. There is currently no standardised template for a discharge summary used within Monash Health. Well-defined criteria for the quality of a discharge summary is lacking [1] . However, reviews of literature agree that good quality discharge summaries should avoid error, efficiently communicate information necessary for the ongoing care of a patient, and increase the quality of care of a patient [1-2] . Time pressure in hospitals, outpatient clinics and GP practices does (...) components of a discharge summary as described by literature; these include recommendations on the content, format, style and processing of a discharge summary. Components that are not frequently used in discharge summaries should also be considered where relevant to a patient’s ongoing care. More importantly, clinicians should always ensure that components in the discharge summary are filled up adequately and correctly. References 1. Unnewehr M., Schaaf, B., Marev, R., Fitch J. & Friederichs H. (2015

2019 Monash Health Evidence Reviews

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>